Thompson Davis & Co’s Titan Pharmaceuticals TTNP Stock Holding History

Thompson Davis & Co’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Hold	0	–	-$2K	–	1201
2017 Q2	–	Hold	0	–	–	–	1001
2017 Q1	–	Sell	-4	Closed	-$56.3K	–	947
2016 Q4	$65K	Hold	4	–	–	0.11%	200
2016 Q3	$95K	Hold	4	–	–	0.17%	144
2016 Q2	$89K	Buy	4 +1	+33%	+$21.3K	0.14%	155
2016 Q1	$47K	Hold	3	–	–	0.07%	254
2015 Q4	$48K	Buy	+3	New	+$48.9K	0.07%	263

Other funds holding TTNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MERSOM

Municipal Employees' Retirement System of Michigan Lansing, Michigan $8.81B AUM 10.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

WPA

Winning Points Advisors Boca Raton, Florida $74.8M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Thompson Davis & Co's TTNP Position: Q3 2017 in Review

Thompson Davis & Co held its Titan Pharmaceuticals (TTNP) position steady in Q3 2017 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1201.

Thompson Davis & Co first reported a position in TTNP in Q4 2015 and has held it in 5 quarters since. The position peaked at $95K in Q3 2016. 24 funds tracked by Wall St. Rank hold TTNP as of Q3 2017.

Thompson Davis & Co held 0 shares of Titan Pharmaceuticals worth $0 as of Q3 2017.
Thompson Davis & Co left its Titan Pharmaceuticals share count unchanged in Q3 2017.
Titan Pharmaceuticals made up ﹤0.01% of Thompson Davis & Co's portfolio in Q3 2017, its #1201 holding.
Thompson Davis & Co first reported a position in Titan Pharmaceuticals in Q4 2015 and has held it in 5 quarters since.
Thompson Davis & Co's Titan Pharmaceuticals position peaked at $95K in Q3 2016.
24 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2017.

Based on Thompson Davis & Co's 13F filing for Q3 2017, filed 30 Oct 2017.